In addition, the PD-1 antibody nivolumab was already approved in 2016 for the treatment of patients with R/M HNSCC who have progressed on or after platinum-based chemotherapy[5]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.